Companies Dominating the Oligonucleotide API Landscape
- Ionis Pharmaceuticals, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Jazz Pharmaceuticals plc
- BIOGEN INC.
- Sarepta Therapeutics, Inc.
- Alnylam Pharmaceuticals, Inc.
- Corden Pharma International GmbH
- Nitto Denko Avecia, Inc.
- Merck KGaA
- Ajinomoto Co., Inc.
- Kaneka Eurogentec S.A.
Browse Key Market Insights with Data Illustration:
In the News
-
Ionis Pharmaceuticals, Inc. in collaboration with Biogen Inc., has announced the results of the investigation of the use of antisense oligonucleotide (ASO) for people with C9orf72-associated amyotrophic lateral sclerosis (ALS).
-
Jazz Pharmaceuticals plc has announced that its Zepzelca (Lurbinectedin) has been approved by the U.S. Food and Drug Administration(FDA), for treating adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
